CRESCENT BIOPHARMA, INC. — Director's Dealing 2016

Oct 4, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: GLYCOMIMETICS INC (GLYC)
CIK: 0001253689
Period of Report: 2016-10-03

Reporting Person: Thackray Helen M. (VP Clinical Development, CMO)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2016-10-03	Common Stock	S	3900	$7.00	Disposed	156715	Direct
2016-10-03	Common Stock	S	100	$7.01	Disposed	156615	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 31, 2016.